Augmentation of the Human Immune Response by Cyclophosphamide

Cancer Research

Volumn 42, Issue 11, 1982, Pages 4862-4866

  Berd, David ^a,b   Mastrangelo, Michael J ^a,d   Engstrom, Paul F ^a,b   Paul, Anthony ^a   Maguire, Henry ^a,c  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 3,4 DINITROBENZENE; CARMUSTINE; CHLOROZOTOCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; FLUOROURACIL; KEYHOLE LIMPET HEMOCYANIN; LOMUSTINE; METHOTREXATE; MITOGUAZONE; MITOLACTOL; MITOMYCIN; SEMUSTINE; TAMOXIFEN; TEGAFUR; TRIMETHYLCOLCHICINIC ACID; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; BLOOD AND HEMOPOIETIC SYSTEM; CANCER; CANCER CHEMOTHERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; COLON CANCER; COLON CARCINOMA; DRUG THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOPOTENTIATION; LARGE INTESTINE; MELANOMA; METASTASIS; RECTUM CANCER; RECTUM CARCINOMA; RETICULOENDOTHELIAL SYSTEM; THERAPY;

AGED; ANTIBODY FORMATION; COLONIC NEOPLASMS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; RECTAL NEOPLASMS;

EID: 0020446174     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Askenase, P.W., Hayden, B.J., and Gershon, R.K. Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J. Exp. Med., 141: 697–701, 1975.
2. Berd, D., Wilson, E.J., Bellet, R.E., and Mastrangelo, M.J. Effect of 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (methyl-CCNU) adjuvant therapy on immune responses of patients with malignant melanoma. Cancer Res., 39: 4472–4476, 1979.
3. Braun, D.P., and Harris, J.E. Effects of combination chemotherapy on immunoregulatory cells in peripheral blood of solid tumor cancer patients: correlation with rebound overshoot immune function recovery. Clin. Immu-nol. Immunopathol., 20: 193–214, 1981.
4. Brock, N., and Wilmanns, H. The action of a cyclic phosphamide ester of nitrogen mustard on experimental tumors in rats: therapeutic effects and pharmacological properties of B518 ASTA. Dtsch. Med. Wochenschr., 83: 453–458, 1958.
5. Campbell, D.H., Garvey, J.S., Cremer, N.E., and Sussdorf, D.H. Methods in Immunology, pp. 116–120. New York: W.A. Benjamin, Inc., 1970.
6. Chiorazzi, N., Fox, D.A., and Katz, D.H. Hapten-specific IgE antibody response in mice. VI. Selective enhancement of IgG antibody production by low doses of X-irradiation and by cyclophosphamide. J. Immunol., 117: 1629–1637, 1976.
7. Debre, P., Waltenbaugh, C., Dorf, M.E., and Benacerraf, B. Genetic control of specific immune suppression. IV. Responsiveness to the random copolymer L-glutamic50-L-tyrosine50 induced in BALB/c mice by cyclophosphamide. J. Exp. Med., 144: 277–281, 1976.
8. Diamantstein, R., Willinger, W., and Reiman, J. T-Suppressor cells sensitive to cyclophosphamide and to its in vitro active derivative 4-hydroperoxycy-clophosphamide control the mitogenic response of murine splenic B cells to dextran sulfate. J. Exp. Med., 150: 1571–1577, 1979.
9. Glaser, M. Augmentation of specific immune response against a syngeneic SV40-induced sarcoma in mice by depletion of suppressor T cells with cyclophosphamide. Cell. Immunol., 48: 339–345, 1979.
10. Hengst, J.C.D., Mokyr, M., and Dray, S. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice. Cancer Res., 40: 2135–2141, 1980.
11. Herberman, R.B. Immunologic approaches to the diagnosis of cancer. Cancer (Phila.), 37: 549–561, 1976.
12. Hunziker, N. Effect of cyclophosphamide on the contact eczema in guinea pigs. Dermatologica (Basel), 136: 187–191, 1968.
13. Maguire, H., Berd, D., Engstrom, P., Paul, A., and Mastrangelo, M. Cyclophosphamide (CY) increases the acquisition of T-cell immunity in patients with melanoma and colo-rectal cancer. Proc. Am. Assoc. Cancer Res., 22: 279, 1981.
14. Maguire, H.C., Jr., and Ettore, V.L. Enhancement of dinitrochlorobenzene (DNCB) ocntact sensitization by cyclophosphamide in the guinea pig. J. Invest. Dermatol., 48: 39–43, 1967.
15. Maguire, H.C., Jr., Mailbach, H.I., and Minisce, L.W. Inhibition of guinea pig anaphylactic sensitization with cyclophosphamide. J. Invest. Dermatol., 36: 235–236, 1961.
16. Ozer, H., Cowens, J.W., Nussbaum, A., Mihich, E., and Colvin, M. Human immunoregulatory T subsets function defined in vitro by cyclophosphamide metabolites. Fed. Proc., 40: 1075, 1981.
17. Polak, L., Geleick, H., and Turk, J.L. Reversal by cyclophosphamide of tolerance in contact sensitization. Immunology, 28: 939–942, 1975.
18. Rollinghoff, M., Starzinski-Powitz, A., Pfizenmaier, K., and Wagner, H. Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J. Exp. Med., 145: 455–459, 1977.
19. Santos, G.W., Owens, A.H., and Sensenbrenner, L.L. Effects of selected cytotoxic agents on antibody production in man: a preliminary report. Ann. N.Y. Acad. Sci., 114: 404–422, 1964.